"Disease Progression" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
| Descriptor ID |
D018450
|
| MeSH Number(s) |
C23.550.291.656
|
| Concept/Terms |
Disease Progression- Disease Progression
- Disease Progressions
- Progression, Disease
- Progressions, Disease
|
Below are MeSH descriptors whose meaning is more general than "Disease Progression".
Below are MeSH descriptors whose meaning is more specific than "Disease Progression".
This graph shows the total number of publications written about "Disease Progression" by people in this website by year, and whether "Disease Progression" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 7 | 7 |
| 1997 | 0 | 10 | 10 |
| 1998 | 0 | 15 | 15 |
| 1999 | 0 | 25 | 25 |
| 2000 | 0 | 22 | 22 |
| 2001 | 0 | 29 | 29 |
| 2002 | 0 | 24 | 24 |
| 2003 | 0 | 49 | 49 |
| 2004 | 0 | 31 | 31 |
| 2005 | 0 | 41 | 41 |
| 2006 | 0 | 40 | 40 |
| 2007 | 0 | 53 | 53 |
| 2008 | 0 | 44 | 44 |
| 2009 | 4 | 49 | 53 |
| 2010 | 4 | 55 | 59 |
| 2011 | 9 | 61 | 70 |
| 2012 | 4 | 65 | 69 |
| 2013 | 4 | 61 | 65 |
| 2014 | 6 | 63 | 69 |
| 2015 | 11 | 87 | 98 |
| 2016 | 6 | 73 | 79 |
| 2017 | 8 | 87 | 95 |
| 2018 | 7 | 90 | 97 |
| 2019 | 10 | 107 | 117 |
| 2020 | 6 | 85 | 91 |
| 2021 | 7 | 67 | 74 |
| 2022 | 0 | 39 | 39 |
| 2023 | 0 | 42 | 42 |
| 2024 | 20 | 39 | 59 |
| 2025 | 6 | 67 | 73 |
| 2026 | 0 | 21 | 21 |
To return to the timeline,
click here.
Below are the most recent publications written about "Disease Progression" by people in Profiles.
-
Cardiac Resynchronization Therapy: A Review. JAMA. 2026 May 26; 335(20):1796-1807.
-
Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials. Lancet. 2026 May 23; 407(10543):2027-2039.
-
Cigarette smoke induces FASN-dependent fatty acid metabolic rewiring to drive bladder cancer progression. Cancer Lett. 2026 Aug 10; 653:218562.
-
Differences in gene expression may contribute to the racial differences in the risk of MASLD. PLoS One. 2026; 21(5):e0345383.
-
Systematic identification of cell-cell interactions associated with the severity of patients with Alzheimer's disease. J Alzheimers Dis. 2026 Jun; 111(3):1156-1167.
-
POD24 is a novel determinant of prognosis in patients with Waldenstr?m macroglobulinemia. Blood Adv. 2026 Apr 14; 10(7):2322-2327.
-
Derivation and Validation of Risk Prediction Models for Cardiovascular and Kidney Outcomes of Non-ST-Segment-Elevation Acute Coronary Syndrome in Patients With Chronic Kidney Disease. J Am Heart Assoc. 2026 Apr 21; 15(8):e045139.
-
Predictive models for ataxia progression and conversion in spinocerebellar ataxia type 1 and 3. Brain. 2026 Apr 07; 149(4):1268-1277.
-
Progressive cardiac phenotypes and reduced reversibility from long-term CUGexp RNA expression in a DM1 mouse model. JCI Insight. 2026 May 08; 11(9).
-
Dynamic progression of ectopic lymphoid structure formation in lacrimal glands of a Sj?gren's disease murine model. Front Immunol. 2026; 17:1797691.